Unwanted side effects were mild in all patients. Efficacy of Imiquimod ( Aldara ) 5% cream for basal cell carcinoma in transplant patients.Imiquimod ( Aldara ) 5% cream has proven cipro antibiotic and pregnancy to be effective in superficial and nodular basal cell carcinomas in nonimmunosuppressed patients and treating squamous cell carcinomas in situ in transplant valacyclovir patients. At our unit, four renal transplant patients and one cardiac transplant patient were diagnosed with 10 basal cell carcinomas in 2001. Imiquimod ( Aldara ) 5% cream (Aldara, a novel topical immune response modifier, has valacyclovir been approved for the topical treatment of anogenital HPV-induced average salary forensic chemist warts. The third patient sho marked response only when topical Imiquimod ( Aldara ) was intermittently supplemented by intralesional interleukin (IL)-2 for valtrex 2 weeks.
Five basal cell carcinomas received Imiquimod ( Aldara ) 5% cream at night four times weekly for 6 weeks, without occlusion, and the other five tumours were treated on 5 nights per week for 5 weeks. More than 15, cutaneous in-transit metastases of malignant melanoma in unilateral localization on the leg were treated topically with Imiquimod ( Aldara ) 5% cream. The objective of this open-label study was to determine the efficacy of Imiquimod ( Aldara ) 5% cream in treating basal cell carcinoma in transplant patients. Twice daily application under occlusive conditions for a period of 21-28 weeks resulted in >90% aldara regression of cutaneous metastases in 2 patients.
Overall, Imiquimod ( Aldara ) as a single agent or in combination with intralesional IL-2 may be a promising immunomodulatory compound for the adjuvant topical treatment of patients with multiple cutaneous metastases of malignant melanoma. Imiquimod ( Aldara ), a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.BACKGROUND. In addition, several studies have demonstrated antitumoral activity in solar keratoses, superficial basal cell carcinomas and Bowen's disease.
Four tumours were superficial, three nodular and three infiltrative. Biopsies taken 6 weeks after the end of treatment sho no tumour in seven of 10 of the cases. Three patients with multiple, i.e. Notably, all four superficial basal cell carcinomas, two of the three of nodular lesions and one of the three of infiltrative cases had completely cleared. Given the convincing therapeutic results of Imiquimod ( Aldara ) when used for treating selected types of epithelial skin cancer, we became interested to study Imiquimod ( Aldara ) as an adjuvant for treating cutaneous metastases of malignant melanoma.
.